adamantane has been researched along with Hyperpigmentation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, HS; Jang, WH; Joo, YH; Jung, K; Lee, CS; Lim, KM; Park, M; Park, YH | 1 |
| Baek, HS; Choi, J; Jeong, YS; Joo, YH; Kim, BJ; Kim, JH; Lee, CS; Park, YH; Shin, HJ; Shin, SS | 1 |
1 trial(s) available for adamantane and Hyperpigmentation
| Article | Year |
|---|---|
Antimelanogenic activity of a novel adamantyl benzylbenzamide derivative, AP736: a randomized, double-blind, vehicle-controlled comparative clinical trial performed in patients with hyperpigmentation during the summer.
Topics: Adamantane; Administration, Cutaneous; Adult; Benzamides; Dermatologic Agents; Double-Blind Method; Facial Dermatoses; Female; Humans; Hyperpigmentation; Middle Aged; Seasons; Sunscreening Agents; Young Adult | 2016 |
1 other study(ies) available for adamantane and Hyperpigmentation
| Article | Year |
|---|---|
A novel adamantyl benzylbenzamide derivative, AP736, suppresses melanogenesis through the inhibition of cAMP-PKA-CREB-activated microphthalmia-associated transcription factor and tyrosinase expression.
Topics: Adamantane; Animals; Benzamides; Cell Line, Tumor; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation; Humans; Hyperpigmentation; Melanins; Melanocytes; Melanoma, Experimental; Mice; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Signal Transduction; Skin; Skin Neoplasms | 2013 |